Survodutide

GLP-1 / Glucagon

Weight loss and liver/metabolic positioning

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide
Primary mechanism: Dual GLP-1/glucagon receptor agonism
Primary market use: Obesity/MASH

Pharmacology

Molecular weight (Da): ~4100
Oral bioavailability: N/A
Half-life: ~4-6 d
Route tags: SubQ; Injectable; route-dependent
Evidence level: Clinical
Clinical status: Investigational
Value-for-money score: 6 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Requires ongoing dosing

Sources

https://clinicaltrials.gov/